Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
Related Articles
Integrating priorities at the intersection of cancer and neuroscience
Cancer neuroscience is a rapidly growing multidisciplinary field that conceptualizes tumors as tissues fully integrated into the nervous system. Recognizing the complexity and challenges in…
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update
Journal of Neuro-Oncology – Target population Adults with imaging suggestive of a WHO grade II diffuse gliomas (oligodendrogliomas or astrocytomas) Question In adults with imaging…
Spotlight on Clinical Trials
The abstract submitter is now open for the submission of clinical trial and late-breaking abstracts. The deadline for clinical trial and late-breaking abstracts is 11:59…
Starting the year smarter
To start the year right, Fred Hutch scientists, providers and a patient advocate share tips to help readers keep up with the deluge of health…
PDUFA Date Set for 3-Month Variation of Leuprolide Mesylate in Advanced Prostate Cancer
The FDA has set the PDUFA date for the 3-month, 21-mg variation of leuprolide mesylate in advanced prostate cancer for August 29, 2025.
Treatment Response to Hypomethylating Agents Based on Molecular Risk and Transplant Status Among Patients With MDS
Time to alloHCT may be more impactful than treatment response to hypomethylating agent-based therapy on outcomes for patients with myelodysplastic syndromes, according to research presented…
Pediatric cancer research cut from spending legislation at last minute Republicans quietly removed hard-won pediatric cancer bills – The Cancer Letter
On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown. To access this subscriber-only content please log in or subscribe.If your…
Highs and Lows of Spatially Fractionated Radiation Therapy: Dosimetry and Clinical Outcomes
: Spatially fractionated radiation therapy (SFRT) intentionally delivers a heterogeneous dose distribution characterized by alternating regions of high and low doses throughout a tumor. This…
Mount Sinai Researchers Uncover Why Some Leukemia Cells May Resist Treatment
Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia (AML) and its resistance to a common treatment.
The Targeted Pulse: Looking Back at 2024’s Achievements and Exploring Potential Approvals on The Horizon
In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals,…
